Zirgan
NDC Package 42826-605-50

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Zirgan is ganciclovir is used to treat herpes infection of the eye. Marketed by Sirion Therapeutics, Inc., this product is identified by NDC 42826-605 and is authorized under FDA application NDA022211.

Identification & Billing

NDC Package Code
42826-605-50
Package Description
1 TUBE, WITH APPLICATOR in 1 CARTON / 5 g in 1 TUBE, WITH APPLICATOR
Product Code
11-Digit Billing Format
42826060550

Clinical Specifications

Proprietary Name
Zirgan
Dosage Form
-
Usage Information
Ganciclovir is used to treat herpes infection of the eye. Although ganciclovir stops the growth of the virus, it is not a cure for the herpes infection. Herpes virus continues to live in the body even between outbreaks of infection. However, treating an outbreak may help the sores in the eye to heal faster and lower the risk of complications (such as decreased vision, blindness). Ganciclovir is an anti-viral drug. This medication treats only herpes eye infections. It will not work for other types of eye infections, such as those caused by bacteria. Unnecessary use or misuse of any anti-infective drug can lead to its decreased effectiveness.

Regulatory & Marketing

Labeler Name
Sirion Therapeutics, Inc.
FDA Application #
NDA022211
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
04-30-2010
End Marketing Date
06-24-2010
Listing Expiration
06-24-2010
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 42826-605-50 identifies a specific commercial package of 1 tube, with applicator in 1 carton / 5 g in 1 tube, with applicator of Zirgan, labeled by Sirion Therapeutics, Inc.. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Sirion Therapeutics, Inc. on April 30, 2010. The current certification is valid through June 24, 2010.

What are the primary indications for this medication?

Ganciclovir is used to treat herpes infection of the eye. Although ganciclovir stops the growth of the virus, it is not a cure for the herpes infection. Herpes virus continues to live in the body even between outbreaks of infection. However, treating an outbreak may help the sores in the eye to heal faster and lower the risk of complications (such as decreased vision, blindness). Ganciclovir is an anti-viral drug. This medication treats only herpes eye infections. It will not work for other types of eye infections, such as those caused by bacteria. Unnecessary use or misuse of any anti-infective drug can lead to its decreased effectiveness.

How is this Sirion Therapeutics, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 42826060550. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
42826-605-50
11-Digit CMS (5-4-2)
42826-0605-50

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.